Microelectrode array (MEA) is a powerful technique for the prediction of proarrhythmic liability. One of the main advantages of MEA is its ability to predict unexpected cardiac liabilities and long term chronic effects in vitro.
In this poster, we focus on:
- the ability of the MEA platform to predict chronic long term effects including hERG trafficking
- predicting the cardiotoxicity of BMS-986094 (INX-08189), a hepatitis C therapy which caused death in its clinical trial after multiple weeks
Read our poster to learn more about our research!